 Hey, Fabio. How you doing? Hey, Richie. How's it going? Good. Thank you. I'm doing Thanks, you can hear me. Okay. Yeah, I can hear you great. Thank you for we're already live we've already got over 50 on the stream and I'm very excited to speak to you about this news today. This is very big news Can I ask you just a quick question before I get into the news? Yeah, absolutely. One of our members is in Germany and I know you have an American listing and you have a Canadian listing He's requesting a German listing. Is that something right? Yeah, we're gonna we're valued the Frankfurt absolutely Yeah, you're one of you that visitor is that the only one that's been asking so we're valuing it now To do that and we probably do that. I would say by the sometime before the summertime You get that so it's an it's an active but that's simple as a turn the switch on if you will Okay, great Now let's get into this news because I think this is enormous news the title state Pharma Thera announced a successful completion of pre IND meeting with FDA for the clinical development of ketamine in the treatment of Parkinson's disease Whoa That's big Yeah, yeah, that was one of our Actually, that was our first license that we that we executed with the University of Arizona Um early last year, I should say in the q3 of last year and what the purpose is that the The researchers at the University of Arizona, uh, dr. Scott Sherman and dr. Torsten fault, uh, they serendipity You know, they figured That ketamine Uh was helpful in Parkinson's patients to treat their dyskinesia or their their tremors if you will They originally were looking to with ketamine just to treat some of the their Parkinson's patients pain and some And as you know, it's side effects of Parkinson's patients. If anyone knows who has Parkinson's they they do have a suffer from whether different forms of Depression if you will so What was unique about this is that they found this was about several years back that this their dyskinesia Literally halted some patients From four weeks even up to three months and actually there's public as a publication of paper Which you can find in our investor decor on our website If you'd like to read it to show that these these really I wouldn't like to say miracle type cases But you know Another improvement that how ketamine beyond its depression or pain that can help another subset of patients that was never really Being evaluated for so the good thing with pharmac there Is that now we have the exclusive license to advance ketamine in parkinson's disease? So the idea was to look go to the FDA which is um give you a little education to your um to your viewers here is that the Company or sponsor would look to the FDA for guidance on how To develop the clinical program of the said product So in our case we found the pre-indy meeting Requested the FDA to understand what their expectations are for ketamine to treat in parkinson's disease or more specifically to treat the levodopa induced dyskinesia in parkinson's disease levodopa is a parkinson's is a gold standard in parkinson's patients But however over time it doesn't help So there's an there's an unmet medical need for these patients to have a new therapy that can help stop their dyskinesia So we sent out to the FDA on two fronts one Do they accept for us to of our proposal to conduct a phase two study? To evaluate a number of parkinson's patients in the dyskinesia over a three month period Based on the on the parkinson's kind of primary efficacy scales that's uh been validated in uh in the in parkinson's clinical studies To see if we can get agreement on that study Then the second half is do what is the regulatory pathway that we can pursue with our program? To get commercial approval from the FDA. So there's a number of pathways you can take We opted obviously for that what it's called the 505 b2 Regulatory pathway and what that means is that a company like us Using ketamine which is an approved drug for as for anesthesia Is that we don't have to do all the non clinical or phase one and healthy subjects if you will studies we can leap to a phase two clinical study and more so Evaluate in that phase two study all the different endpoints or Or parameters both from a safety and efficacy of these parkinson patients Which would then the data would set up to allow for us to move towards a pivotal clinical study Which that would probably take place sometime in next year. So this is exciting for us because you literally reduce that timeframe for a drug to be to get approval from whether it's say five Even 10 years on the traditional new drug applications or new drug New chemical entities to an existing one and you can reduce that even to say even anywhere between three to five years For approval and we're already ahead of that So this is this is a really game changer in the sense of for a Parkinson's patient And that's and that's evident with the people we have on board with us not beyond beyond the inventors from the university of Arizona We have dr. Robert hauser from the south South to south florida university then dr. Espe alberta espe from the university of sanitary They are you know leaders in their field. So, you know, this is a really You know a a unique program for us to kind of kick off our clinical stage Pipeline to go to the FDA to and to really actually then expand our ketamine Program in depression in pain and all the other even motor disorders that ketamine could be uh Be useful for so really in essence Pharmacare has become it's kind of involved to the specialty Psychedelic company with a particular focus with with ketamine built from use of novel uses of ketamine But also in formulations for ketamine and delivering in a different way such as a microneedle patch, which we announced even early this week with respect to Our license with professor donnelly's microneedle delivery technology that's already shown to deliver as ketamine, which is the The same drug that j and j Markets to patients with depression but in a form of a nasal spray So, you know, we have all these great developments going on and i'm just happy that you know again from our last Interviews that you understand you recognize our value of our company and really sharing our story with your With your viewers and followers. So thank you ritchie for that It's it's important that we find undervalued under depreciated under exposed companies I mean that's what we do best and it's important for the companies to gain the exposure. So we kind of help each other here. It's Something that parkinsons is something that is is destroying families. You know, it's a terrible disease What is it exactly that? You're doing like how is it helping people with parkinsons? What is exactly what is it doing? Like how is it helping people with parkinsons? Can you explain that? Yeah, so yeah, absolutely. If you know anyone with parkinsons who has parkinsons a lot of it and you can just take the The case of michael j fox. So everyone, you know, well known Parking great great exam patients, right? So everyone can now visualize in that and you see how not only from the movements But the tremors the shaking which is called we call this the dyskinesia of these patients I'd experience on a daily basis at multiple times during the day now imagine a drug that can not only Reduce these tremors and these sporadic movements if you will On a daily basis, but for a longer period of time, but also halting that that's what ketamine is doing And that's just from you know, what parkinsons does to these patients In as a side effect is they're always experiencing some sort of pain There is definitely depression. That's because of being a Socially limited into what they can do now the idea of going to the grocery store going to your car when the grocery store And in shop that becomes a difficult endeavor so ketamine Showing even at these early stage with these patients that's been that's been tested already That they're stopping this kind of these dyskinesia or tremors. So this is a very yeah, so it's it's a game changer, right? So now it's our job is to now look ketamine's out there, right? But it can't be used to treat these parkins because there's no there's no clinical on a I guess you can say clinical meaningful basis to have that approval So that's what we're trying to do in these clinical studies is now to take a larger set of population showing it being statistically significant that it can improve the Or decrease the the dyskinesia in these patients and offer another option And their treatment for for Parkinson's and the spillover or what you like to say is the gravy is You know that can also have help on the pain side of Of these patients of these Parkinson's patients as well as even depression because now you've improved their their way of living with this therapy and that's what we're set out to do Now Fabio we work with so many companies and branding is everything One thing I've noticed with pharma there you've got pharma there, which is your subsidiary But you're operating under new scope capital corp. Yes. Am I predicting the future here? You're going to do a name change to pharma there Yes, absolutely. So that's so so so Richie. This is one of the most painful things that Besides, you know, dealing with fda and what all these other having our name at new scope This is a legacy issue that we had to deal with when we Merge with this company and conduct a non-offering Perspectives to go list on the csc. So we kind of adopted that name So really new scope is the parent, but it's fully operated under pharma there. So Yes, shareholders, we will do that flip where we'll we are going we're in the process of changing our name So that there's a commonality in how we describe our company So this is be quite frankly, uh, and I see now your you know, you explain yourself It's it's irritating to me and I'm the CEO of the company That's why I'm bringing it up because I can see the way you're writing your press releases new scope But then right in the beginning it's pharma there. So it's like it's a little bit of a disconnect for investors And I think by having the name change And I've seen this with other companies It's going to be a major catalyst because there will be no disconnect. There'll be no confusion It'll be pharma there and then that's all you have to put in your press releases. That's all that everyone will be mentioning That's the name everyone will be talking about But a lot of times I'm talking about new scope capital that I'm talking about pharma there So people get confused. They think they're two different deals Um, yeah Right. So, uh, I just figured that it would be a natural progression to just move towards pharma there as your as the name that you guys were operating under Yes, and absolutely that's that's that's that's going that's going in process So that's that's definitely on the top one of the top priorities for our company. That's fantastic Now as an undervalued under appreciated under exposed company that's just getting started that's trending up All this great news coming What else can investors look forward to I know you guys have a lot of things going on Is there anything else that we can look forward to in addition to what you're working on right now with this With this uh, this this deal with Parkinson's Yeah, absolutely. So, you know, right now with the Parkinson's just to kind of Close this loop is that our next stage is to file what it's called is an investigational new drug application to the FDA To allow us to conduct our phase two studies and also set the foundation For the clinical development of that program. So that's like the next catalyst for this specific program Now the next one of them another major catalyst that we're moving towards is our catabit program Which catabit is the combination of ketamine and another drug called betaine that combination Which is pat and it's been past it's been granted and we did we do have the worldwide rights to this program Is that this is a formulation that will allow this combination for us will allow in the treatment for Treatment resistant depression. That's our target. We're going after so our next step with this program Is to file our pre-ind meeting with the FDA to See to to understand the clinical study the phase two clinical study that we're going to be proposing to them For allows to conduct for these treatment to resistance to depression. So in that within that time We're also building our core competency or advisory board in depression so that we can really have a You know a world I guess you can say a a leading expert on this program to really drive this over So that would be the from the catabit program another the the foundational for depression Which is then can also I consider this this this program more of a program a pipeline program for other indications That we can go after such as ptsd Maybe it would be anxiety anything that ketamine could be useful for this combination What it does is that it reduces the side effects and put and at some cases even limit Potentially to eliminate the side effects that ketamine has such as police sedation amnesia nausea all these things and specifically with ketamine using on a chronic basis right and There are other side effects that can that can also happen that would any institutional type disorders as well So we can eliminate that or even reduce the side effects over the long term with this formation So in fact, you know, we we under promoted in terms of what this the potential is but because i'm particularly a more of a fundamentalist I like to the data speak for itself and then let's see audience whether it's the medical community investor community to decide whether This is the the fact or the treatment that's coming to be there's great treatments going as being worked on now I mean you look at even compass with their psilocybin program You have uh, j and j who has their spravado nasal spray and that's as ketamine spray that's marketed right now the differences between hours and bears is that What we're trying to do that's differentiated is that we will allow to give the patient to treat Their ailments, which is say depression at the comfort of the whole home Whether it would be in a micro needle patch Or in a in a in a drug that allowed to take to the use that home on on on on that daily basis as opposed to Other treatments such as psilocybin or ketamine you have to go to the clinic You know do the whole Set up and whatnot and you can stay up to even between several hours to even up to eight hours For the day for that single treatment. So we're trying to change that game to what People are used to to treat their ailments is go to the pharmacy get your prescription bring it home take it and you know Have it how to make it work so it can control or even treat their their Their disease so that's what we're doing with this with with catabetic and you'll see that progress forward with that now With that not to just gloss over that but you'll see that that's going to be More milestones coming to be we also have our psilocybin program that we're actually working To look at psilocybin for treatment and stroke and then the treatment of traumatic brain injury even specifically concussions Now we're conducting early stage clinical pre clinical research and with that with that Effort is that's going to be taught is going to allow to open up the field And maximize the potential psilocybin But not only with that we have other IP that's involved with psilocybin And we are because we've kind of now evolved this specialty Academy company We are going to and we've signed a binding lli with revive therapeutics that allow them to continue their psilocybin efforts And we're parking if you will our program to to revive And for in exchange for another school's amount fee, which we'll announce once we close it But that will allow for the company to have a non dilutive Funding for the company to allow us to fund our phase two program So this is very unique because a lot of the a lot of the you know the questions in the market is Okay, this company's going to phase two. It's going to need money to to To advance this and whatnot and this is a non dilutive way for us To now advance our phase two without having that pressure on the stock if you say for us to go out to The markets to raise capital. So we are well-primed or positioned To for for pharma there for I guess newscope is to take it to be to become at the next level Which they'll you know with our valuation you can see and your investors are probably more educated than I am in this Is that there's a substantial disconnect between our valuation and Our peers, right? I mean you can see that's evidence, but then you look at our company It's like, okay, they're in this psychedelic sector check How about their patent situation? Well, we have 19 granted patents patent applications that we have for worldwide rights Okay, that's pretty good check. We have a clinical Uh product pipeline that's going into phase two for large unmedical needs Parkinson's depression PTSD eventually even in pain all with our unique formulation that will change the way How these diseases are being treated. Okay, check So now we're on this, you know, this cusp of do you know, we're here now is to make The community understand about our company Um and to understand that wow, okay, we see this this disconnect and you know and to kind of You know move us forward to the next level to allow us to Continue our developments and bring these products to eventually to market So, you know, these are these these these things with the company now we're going through we're a fairly new company as well So, I mean we I founded the company last year, you know early up to 2020 so and things do take time But now the timing is right for us to get to that next level Do you have a goal? uh We're we got a lot of uh members here that that like your company that already own the stock a lot of them A lot of them are interested in getting into the stock. Do you have a goal as far as market cap? Your market cap is a baby market cap right now. Yeah, I think that 100 million market cap is very reasonable I think you're probably around a 35 million market cap right now. If I do my the number is correct Uh, what like 70 million shares at 50 cents about a 35 million market cap so yeah, needed so 100 million market cap. Is that like a goal of yours? I mean 100 million market cap will put you guys at about a dollar 50 Is that something that is reasonable? Do you guys look at that? Is that a goal that you you look to achieve? Is that even matter to you? Is that something you guys think about? Yeah, like we to have some sort of goal I mean it would be foolish for me to say that we would like to have or our goals to be 100 million We're not in the and we're not doing what we're doing to be 100 million market cap company That's just evident We're in the we're the goal is to take this company to a billion dollar market cap Right and how we're going to do it is evident in our pipeline We're we're going after large indications that already had scientific and clinical validation And we're doing a unique way. So if you take a company like like compass, okay Who is in phase 2b clinical says what they're still aside in for tumor resistant? They're at I guess a one and a half two billion dollar market cap American you have a company like mine med who now doesn't have an fda Program they're doing a lot of work out in europe in lsd and mda and I applaud them because I think they're doing a They're doing great work and their market cap that I believe one a half billion Right and then you have these other players who are kind of treading in that say 100 to 250 million market cap range, but they all have different businesses because some may have a A clinic a clinic strategy where they're expanding in the physical clinics to treat these patients Other ones are in the kind of these biotech psychedelic companies, you know, like side and whatnot They have their own little delivery system and they're trying to sell a side and whatnot and they're trading on but they have great backing They have great investors, right? You know, we're just new we came out of we came out of just like, you know, race funds through I guess more of like friends and family and whatnot And then now institutions and now we've kind of built this Quietly this pipeline where if you were to put our company in one of the other companies I've just mentioned, you know That would propel them to another level or even even to even justify those types of market caps as well So again, do I look at the market caps of these other companies? As you can see I do Do I have a set goal of a specific like where we reach one end and we're done with we achieve? Absolutely not but we are shooting for that star So to suggest that we could be a billion dollar market cap a half billion dollar market cap or whatever million market cap That's the investors are going to have to do their due diligence to dig deep and to understand where's that disconnect? We are an open-based company here. You can go on our deck. You can see every pattern We have license you can see all the clinical data we have there's nothing that That's least to the eye of the beholder here and everyone could do their own due diligence on it Fabio super impressed with everything you're doing We're running out of time. If there's one thing you want investors that are watching to know About pharma there. What would it be? The bottom line is we're a young company that's just Or in the cuts of the going to the next level with our clinical or ketamine based Program in in Parkinson's and depression and will be Conducting clinical trial soon which that value inflection point of that of our company will will marry with The other of our peers. So, you know, all I can say is to your viewers is just Continue to follow us continue to try to root for us and even root for everyone in the sector of psychedelics because You know, it's time that the game has to change of how Patients are being treated for their mental health or neurological and pain disease the drugs out there right now The side effects they're just not they don't they're not up to snuff So we're all doing our part to make this world a better place And you know, we we've carved an area that we can we can definitely help in that in that endeavor. So again I thank everyone for viewing and Just if you have any questions, you can call me go on our website at pharma there.com And you can email me at info at pharma there.com or our 1 800 numbers there Have any questions feel free to call me anytime fantastic the CEO of pharma there new scope capital corp symbol ph rm in canada ph rrf Fabio did mention that they will be looking at getting a german listing by the summer So stay tuned get your popcorn ready. Put them on your radar. Put them on I believe this is a company that's undervalued underappreciated underexposed and it's just getting started Thank you for your time fabio and have a great day. Awesome. Thank you rich and thank you everyone Take care. You've upped a good work and we hope to have you on the show soon Absolutely anytime. Thank you fabio. Cheers. Take care. Bye. Bye All right guys, thank you guys for watching. Hope you guys enjoyed the video Hope you guys enjoyed the show. If you guys have any other questions, please feel free to put it in the chat Other than that we wish you guys